Table 2. The sensitivity of conjunctival melanoma cell lines to Vemurafenib, Dabrafenib, MEK162 and MK2206.
| Cell line | Mutation | Vemurafenib (μM) | Dabrafenib (μM) | MEK162 (μM) | MK2206 (μM) |
|---|---|---|---|---|---|
| CRMM1 | BRAF V600E | 0.99±0.07 | 0.10±0.01 | 0.09±0.02 | 4.90±1.25 |
| CRMM2 | NRAS Q61L | >6.4 | >1.25 | 0.05±0.01 | 9.67±0.91 |
| CM2005.1 | BRAF V600E | 0.10±0.01 | 0.003±0.001 | 0.03±0.01 | 16.4±1.61 |
Cells were exposed to the single agent for 72 hrs to assess the cell viability. And the dose-response IC50 values were calculated using Compusyn software. Data were presented as the mean ± SD from at least 3 independent experiments.